Yaqin Li
Papers
1
Total Citations
27
H-Index
1
About
Yaqin Li is a pioneering researcher in hematology and molecular therapeutics, whose work centers on developing novel treatments for beta-hemoglobinopathies such as sickle cell disease and beta-thalassemia. Her major contribution lies in the discovery and validation of small-molecule inducers of fetal hemoglobin (γ-globin), a therapeutic strategy that can dramatically ameliorate disease severity. In her landmark 2015 study, Li adapted a high-throughput screening (HTS) platform using a LCR-γ-globin promoter-GFP reporter assay to identify novel compounds capable of reactivating fetal globin expression. She then demonstrated that these agents are orally bioavailable and active in vivo in anemic baboons and transgenic mice, providing a critical proof-of-concept for clinical translation. This work, cited 27 times, represents a significant step toward safer, more accessible treatments for millions of patients worldwide. Li’s research bridges the gap between high-throughput drug discovery and preclinical validation, showcasing her ability to translate molecular insights into tangible therapeutic candidates. Her achievements highlight her as a key figure in the fight against genetic blood disorders.
Research Focus
Key Achievements
Top Papers
- 1